论文部分内容阅读
目的探讨血浆溶血磷脂酸(LPA)检测在妇科恶性肿瘤特别是卵巢癌诊断中的临床意义。方法检测191例妇科恶性肿瘤和40例妇科良性疾病患者及40例健康献血员血浆溶血磷脂酸含量,同时测定卵巢癌患者血浆CA125含量,并作对比分析。结果卵巢癌组、宫颈癌组及子宫内膜癌组患者血浆LPA水平分别为(5.98±2.49)、(4.81±2.12)和(4.56±2.16)μmol/L与正常对照组的(2.31±0.45)μmol/L比较,有显著性差异(P均<0.01),三者阳性率分别为86.3%、62.5%及65.0%;乳腺癌组、白血病组及妇科良性疾病组与正常对照组比较,有显著性差异(P>0.05);血浆LPA和CA125对卵巢癌诊断的敏感性和特异性分别为86.3%、75.0%和92.3%、73.1%。结论血浆LPA检测对妇科恶性肿瘤特别是对卵巢癌的诊断及鉴别诊断可能具有潜在的临床应用价值。
Objective To investigate the clinical significance of detecting plasma lysophosphatidic acid (LPA) in the diagnosis of gynecologic malignancies, especially ovarian cancer. Methods 191 cases of gynecologic malignancies and 40 cases of benign gynecological diseases and 40 healthy blood donors were tested for plasma lysophosphatidic acid levels. Meanwhile, plasma CA125 levels in ovarian cancer patients were measured and compared. Results The levels of LPA in the ovarian cancer group, cervical cancer group and endometrial cancer group were (5.98 ± 2.49), (4.81 ± 2.12) and (4.56 ± 2.16) μmol / L, respectively, compared with those in the normal control group (2.31 ± 0.45) (P <0.01). The positive rates of the three groups were 86.3%, 62.5% and 65.0% respectively. There was a significant difference between the breast cancer group, the leukemia group and the benign gynecological disease group and the normal control group (P> 0.05). The sensitivity and specificity of plasma LPA and CA125 in the diagnosis of ovarian cancer were 86.3%, 75.0% and 92.3%, 73.1% respectively. Conclusion Plasma LPA detection may have potential clinical value in the diagnosis and differential diagnosis of gynecological malignant tumors, especially ovarian cancer.